Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is expected to experience continued growth under strong leadership, with a focus on branded drugs and a diverse pipeline. The company's recent shift to branded drugs has led to improved revenue and credit rating, and potential M&A opportunities could further bolster growth. The launch of their new drug, UZEDY, for nervous system disorders and expansion into international markets show promising potential for the company's growth in the long-term.

Bears say

Teva Pharmaceutical Indus is facing a multitude of challenges that may hinder its growth, such as high debt levels, declining sales for its major drug Copaxone, increased competition in the generic drug market, and ongoing legal issues surrounding opioid sales. Additionally, the company's acquisition of Allergan's generics business has not met expectations, resulting in a write-down of $1.6 billion. All of these factors contribute to a negative outlook for TEVA's stock.

Teva Pharmaceutical (TEVA) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Buy based on their latest research and market trends.

According to 11 analysts, Teva Pharmaceutical (TEVA) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.